Quantitative analysis for Nuvectis Pharma Inc. Common Stock (NVCT) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (66.0) (grade B). 27 signals analyzed (22 differentiated alt-data).
NVCT stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-15 | $8.85 | $8.41 | $8.50 |
| 2026-04-27 | $9.09 | $8.74 | $8.75 |
| 2026-05-07 | $10.49 | $9.80 | $10.32 |
| 2026-05-19 | $10.58 | $10.08 | $10.30 |
| 2026-06-01 | $9.99 | $9.51 | $9.75 |
| 2026-06-11 | $10.55 | $9.94 | $10.51 |
| 2026-06-24 | $24.71 | $17.55 | $24.48 |
| 2026-07-07 | $19.89 | $18.86 | $19.20 |
| 2026-07-17 | $19.21 | $18.04 | $19.14 |
| 2026-07-29 | $21.29 | $19.75 | $20.69 |
| 2026-08-10 | $18.90 | $18.30 | $18.88 |
| 2026-08-21 | $23.93 | $22.83 | $23.56 |
How Nuvectis Pharma Inc. Common Stock stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AZN | AstraZeneca PLC | $290.7B | — |
| NVS | Novartis AG | $287.1B | — |
| NVO | Novo Nordisk A/S | $200.3B | — |
| SNY | Sanofi | $107.6B | — |
View all Health Care stocks by valuation and signals →
Nuvectis Pharma Inc. Common Stock (NVCT) scores Buy (66.0), and the composite conceals a 98-point disagreement between its dimensions. It is strongest on ML forecast at 99 and analyst consensus at 79, and weakest on competitive moat at 1. A stock can carry ML forecast that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| ML forecast | 99 |
| analyst consensus | 79 |
| valuation | 77 |
| technicals | 64 |
| earnings quality | 52 |
| competitive moat | 1 |
StoQuant analyzes 27 signals (22 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Nuvectis Pharma Inc. Common Stock (NVCT): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/NVCT"><img src="https://stoquant.com/badge/NVCT.svg" alt="Nuvectis Pharma Inc. Common Stock (NVCT) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Daily Q-Score changes, insider buy clusters, and ML forecast updates for the tickers you follow. Email only, no account needed. See a sample digest.